A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability (Veracept)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Age: Between 17 - 35 Years
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required